Cancers | Clinical Development Trends

By 2035, the incidence and mortality in these cancers is expected to rise by rates of 51-97% and 63-101%, respectively. Therefore it is imperative that the current clinical landscape of these cancers be examined and thoroughly understood in order to aid in the strategic planning needed to facilitate development of effective therapies to combat these cancers in the future. Using data exported from Citeline’s competitive intelligence product suite in April 2014, an analysis of over 6500 trials from 1988 to 2014 in these five prevalent Asian cancers included locations, sponsorship, recent clinical activity, primary drugs and mechanisms of action, primary endpoints and incorporation of pharmacogenomic biomarkers. Supportive care trials in these five cancers were excluded from this analysis.

Highlights in this white paper include:

This important white paper provides an in-depth analysis of the clinical trial landscape in 10 Asian countries related to effective therapies of treatment of the five most prevalent and life-threatening Asian cancers.

Top Five Asian Cancers – Trends in Clinical Development

Cancer types by clinical trial locations for all trial statuses
Trial activity by sponsor types, including industry and non-industry groups
Recent clinical activity and sponsor investment by cancer type and the reasons behind trends in sponsorship
Primary drugs and mechanisms of action
The distribution of primary endpoints and more